Journal
VACCINE
Volume 27, Issue 52, Pages 7346-7351Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.09.043
Keywords
Recombinant BCG; Pertussis; Vaccine; Auxotroph; Complementation; Neonates
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP [96/11539-0]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao Butantan, Sao Paulo, SP, Brazil
- FAPESP Post-Doctoral fellowship [02/01748-4]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [96/11539-0] Funding Source: FAPESP
Ask authors/readers for more resources
Mycobacterium bovis BCG has long been investigated as a candidate for heterologous antigen presentation. We have previously described an rBCG-Pertussis that confers protection against challenge with Bordetella pertussis in neonate and adult mice. In order to obtain stable expression in vivo, we constructed an unmarked BCG lysine auxotrophic and a complementation vector containing the lysine and the genetically detoxified S1 pertussis toxin genes, both under control of the same promoter. Complemented BCG-Delta lysine growth and expression of the pertussis antigen were stable, without the use of an antibiotic marker. Our results show that the complemented rBCG-Delta lysA-S1PT-lysA(+)(kan(-)), which is now suitable to be evaluated in clinical trials, maintains similar characteristics of the original rBCG-pNL71S1PT strain, such as the antigen expression level, cellular immune response and protection against the same model challenge in neonatal-immunized mice. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available